publications High-Cost Therapy Profile: March 2025 Pegzilarginase Intravenous (IV), Subcutaneous (SC) | Immedica Metabolic March 14, 2025 Proposed indications Arginase 1 deficiency (ARG1-D)...

Breadcrumb Home Newsroom Custom Content Publications Drug Approvals Monthly Update: September 2024 PUBLICATIONS Drug Approvals Monthly Update: September 2024 This monthly update of United States...

Get the most value and best outcomes from C&GT Cell and gene therapies (C&GTs) represent breakthrough science, but often come at a high cost. Breadcrumb Home Our solutions Condition management Cell...

Biobetters are just a nickname; they’re based on existing biologics but with a few key differences

Read Drug Approvals Monthly Update: June 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

Perspectives High-Cost Therapy Profile: April Detailed information about prademagene zamikeracel Topical surgical application Date High Cost Therapy Profile Gene therapy/Dermatology Prademagene...

PUBLICATIONS FDA Decisions Expected Drug pipeline for January 2025 December 17, 2024 Your monthly synopsis of new drugs expected to hit the market At Prime Therapeutics (Prime), we have positioned...

Read Drug Approvals Monthly Update: April 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...